Stalicla Seals Deal To Advance Novartis Drug For Cocaine Misuse
Seeking The Right Indication For Mavoglurant
Executive Summary
The biotech has persuaded its fellow Swiss firm that it can advance mavoglurant, a Novartis drug that has failed in Parkinson’s and Fragile X syndrome, for cocaine use and neurodevelopmental disorders.